Record Display for the EPA National Library Catalog

RECORD NUMBER: 4 OF 5

OLS Field Name OLS Field Data
Main Title Induction, Accumulation, and Persistence of Sister Chromatid Exchanges in Women with Breast Cancer Receiving Cyclophosphamide, Adriamycin, and 5-Fluorouracil Chemotherapy.
Author Tucker, J. D. ; Wyrobek, A. J. ; Ashworth, L. K. ; Christensen, M. L. ; Burton., G. V. ;
CORP Author Lawrence Livermore National Lab., CA. Biomedical Sciences Div. ;Duke Univ. Medical Center, Durham, NC. ;National Inst. of Environmental Health Sciences, Research Triangle Park, NC. Epidemiology Branch.;Health Effects Research Lab., Research Triangle Park, NC.
Publisher c1990
Year Published 1990
Report Number EPA/600/J-90/240;
Stock Number PB91-116988
Additional Subjects Antineoplastic agents ; Breast neoplasma ; Cyclophosphamide ; Fluorouracil ; Mutagens ; Lymphocytes ; Reprints ; Sister chromatid exchange ; Doxorubicin ; Intravenous infusions
Holdings
Library Call Number Additional Info Location Last
Modified
Checkout
Status
NTIS  PB91-116988 Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy. 03/04/1991
Collation 8p
Abstract
The induction, stimulation, and persistence of sister chromatid exchanges (SCE's) and high SCE frequency cells (HFC's) was measured in peripheral lymphocytes of women with breast cancer before chemotherapy and on multiple occasions during and after therapy. Chemotherapy consisted of i.v. infusion of cyclophosphamide, Adriamycin, and 5-fluorouracil, administered on day 1 of each of approximately six 21-day cycles. This treatment resulted in a highly significant of SCE's (1.8-fold, P < 0.0001) and HFC's (5-fold, P < 0.0001) measured in samples obtained 1 week after the first therapy. Accumulation of lesions leading to SCE's was measured by comparing samples surrounding the first and last rounds of therapy and was significant for both SCE's and HFC's in most comparisons. Persistence of lesions leading to SCE's was evaluated at multiple times until 9 months after completion of therapy, and both SCE's and HFC's remained significantly elevated throughout this time.